Compare Johnson & Johnson (JNJ) vs Nebius Group NV (NBIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Nebius Group NV — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while Nebius Group NV trades at $221.12 (market cap $59.73B). The key difference: Johnson & Johnson is far larger — about 10.3× Nebius Group NV's market cap, and Johnson & Johnson pays a 2.09% dividend while Nebius Group NV pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Nebius Group NV for 24 Days on average.
| JNJ | NBIS | |
|---|---|---|
Market Cap | $618.09B | $59.73B |
Volume | 6,050,983 | 21,563,700 |
Sector | Health | Technology |
52-Week High | $278.43 | $286.69 |
52-Week Low | $186.00 | $73.87 |
Typical Hold Time | 129 Days | 24 Days |
Enterprise Value | $646.37B | $61.86B |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
NBIS trades at $221.12, down 6.73% over 24 hours amid a bearish technical signal. The stock shows strong analyst support with an 81.82% buy rating and a $288.67 consensus price target, but faces high valuations with a P/E of 845.04 and negative earnings in recent quarters. Recent news highlights AI infrastructure growth potential, including a $37 billion backlog and strategic acquisitions like Inferize, though insider selling and competitive pressures pose concerns.
The outlook for NBIS hinges on executing its AI cloud expansion, with revenue projected to surge from $530 million in 2025 to $1.4 billion in 2026. Risks include elevated debt from aggressive investing, negative net income margins, and potential AI market volatility. The stock offers upside if growth targets are met but remains sensitive to sector sentiment and financing stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Nebius Group NV
Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →
